1900 results
Pathophysiology Euglycemic DKA - Mechanism of SGLT-2 Inhibitors #Pathophys #Endocrine #Euglycemic #DKA #SGLT2 #Mechanism
Pathophysiology Euglycemic ... - Mechanism of SGLT ... Pathophys #Endocrine #Euglycemic ... #DKA #SGLT2 #Mechanism
SGLT2 Inhibitors and Euglycemic DKA

Risk factors for euglycemic DKA in those on an SGLT2i include:
 •
SGLT2 Inhibitors ... and Euglycemic ... Risk factors for euglycemic ... in those on an SGLT2i ... #Euglycemic #DKA
SGLT2 Inhibitors and Cardiovascular Pathophysiology

#SGLT2i #Inhibitors #Cardiovascular #Pathophysiology
SGLT2 Inhibitors ... Pathophysiology #SGLT2i
Pathophysiology of Euglycemic DKA in SGLT2 Inhibitors
 • Kidney: Glycosuria, Natriuresis, ↑ Ketone bodies reabsorption
 •
Pathophysiology of Euglycemic ... DKA in SGLT2 Inhibitors ... Ketogenesis → Euglycemic ... @priti899 #Euglycemic ... #DKA #SGLT2i #Inhibitors
How SGLT2 inhibitors block glucose reabsorption in proximal tubule and improve systemic glucose homeostasis:
https://www.ajkd.org/article/S0272-6386(18)30633-4/fulltext

#Pathophysiology #Mechanism #Nephrology
How SGLT2 inhibitors ... Mechanism #Nephrology #SLGT2
Euglycemic Diabetic Ketoacidosis (EuDKA)
SGLT2 Inhibitors
Increasing Indications
Significant Adverse Drug Effects
Definition of EuDKA
 • Metabolic acidosis with pH
Euglycemic Diabetic ... Ketoacidosis (EuDKA) SGLT2 ... @accpcardprn #Euglycemic
AACE/ACE 2018 Glycemic Control Algorithm

#AACE #2018 #Glycemic #Diabetes #DM2 #Control #Medication #Algorithm #Endocrinology #PrimaryCare #Management
AACE/ACE 2018 Glycemic ... Control Algorithm ... #AACE #2018 #Glycemic ... Control #Medication #Algorithm
Cardiovascular and renal effects comparison between SGLT-2 inhibitors
 - Canagliflozin (Invokana)
 - Dapagliflozin (Farxiga)
 - Empagliflozin
comparison between SGLT ... cardiovascular #renal #SGLT2i
Metabolic Acidosis with Anion Gap - KILU Mnemonic

K - Ketoacidosis
	• DKA
		- With normal glucose, ask if
glucose, ask if on SGLT2 ... - Eugylcyemic ... ketoacidosis in SGLT2 ... inhibitors and SGLT2
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
Clinical Trials of SGLT2 ... ASCVD; signal for SGLT2i ... risk; signal for SGLT2i ... outcomes trial in SGLT2i ... mcclaffertyMD #SGLT2